Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jessica Palicki

Physician Assistant Toledo, OH Physician Assistant

NPI 1841759537 CMS profile 10844630

4235 Secor Rd Bldg 1, Toledo, OH 43623

Open in the dashboard

General payments

$18,863

939 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica Palicki of Toledo, OH is reported in the CMS Open Payments database as having received $18,863 across 939 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,313 161
2024 General $2,487 117
2023 General $4,738 187
2022 General $4,281 246
2021 General $4,044 228

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Palicki
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jessica Palicki were reported at $3,313. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jessica Palicki Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $4,044 $132 $37–$438 $132
2022 $4,281 $155 $48–$522 $149
2023 $4,738 $167 $52–$557 $160
2024 $2,487 $178 $55–$600 $164
2025 $3,313 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. EMD Serono, Inc. $3,085 53 payments
  2. Biogen, Inc. $2,061 96 payments
  3. US WorldMeds, LLC $2,029 101 payments
  4. AbbVie, Inc. $1,762 116 payments
  5. Novartis Pharmaceuticals Corporation $1,027 64 payments
  6. Teva Pharmaceuticals USA, Inc. $801 55 payments
  7. UCB, Inc. $724 50 payments
  8. Janssen Pharmaceuticals, Inc $502 27 payments
  9. Alexion Pharmaceuticals, Inc. $426 16 payments
  10. Lilly USA, LLC $410 23 payments
  11. Other $6,037 338 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,102 923 payments
  2. Consulting Fee $1,160 1 payment
  3. Education $514 10 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $86 5 payments
Products named General payments · program years 2021–2025
  1. Apokyn $1,512 72 payments
  2. TYSABRI $1,199 64 payments
  3. VUMERITY $1,031 53 payments
  4. UBRELVY $995 68 payments
  5. QULIPTA $741 44 payments
  6. MAVENCLAD $706 24 payments
  7. KESIMPTA Neuroscience $539 30 payments
  8. Briviact $528 35 payments
  9. KESIMPTA Neurology $464 33 payments
  10. EMGALITY $331 19 payments
  11. Other $9,877 570 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

1,844

Median for Physician Assistant: 241

Drug cost

$331,716

Median for Physician Assistant: $4,110

Branded share of claims

33.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 80 $81,621
Aimovig Autoinjector Erenumab-Aooe Brand 44 $31,917
Qulipta Atogepant Brand 27 $31,812
Ubrelvy Ubrogepant Brand 27 $28,622
Nourianz Istradefylline Brand 12 $25,219
Rytary Carbidopa/Levodopa Brand 20 $23,295
Ajovy Autoinjector Fremanezumab-Vfrm Brand 25 $19,346
Dimethyl Fumarate Generic 11 $19,231
Emgality Pen Galcanezumab-Gnlm Brand 15 $12,277
Namzaric Memantine Hcl/Donepezil Hcl Brand 14 $10,889

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$22,819

Medicare's payments for the services billed

Medicare patients

165

Average age 69

Services billed

353

97 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 53%
Depression 37%
Diabetes 25%
Ischemic heart disease 24%
Osteoporosis 24%
Chronic kidney disease 22%
Alzheimer's or dementia 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Apokyn
$987 — —
KESIMPTA
$213 — —
NOURIANZ
$125 12 —
Mavenclad
$72 — —
AMYVID
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

939 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record